<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0001845'>Inflammation</z:mp>, which is known to be detrimental to the neurological outcome during the <z:hpo ids='HP_0011009'>acute</z:hpo> phase after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, provides a potential preventative or therapeutic approach for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="6497">Lipoxins</z:chebi> are endogenous lipoxygenase derived <z:chebi fb="0" ids="23899">eicosanoids</z:chebi> and evokes protective actions in a range of pathophysiologic processes </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we evaluated the efficacy of 5 (S), 6 (R)-<z:chebi fb="0" ids="6497">lipoxin</z:chebi> A(4) <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (LXA(4) ME), a stable synthetic analogue of <z:chebi fb="0" ids="6497">lipoxin</z:chebi> A(4) in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> reperfusion injury in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 2h </plain></SENT>
<SENT sid="4" pm="."><plain>Intracerebroventricular administration of LXA(4) ME immediately after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> ameliorated neurological dysfunctions, reduced infarction volume and attenuated neuronal <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, Treatment with LXA(4) ME suppressed neutrophils infiltration and <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation levels; inhibited the activation of microglia and astrocytes; reduced the expression of pro-inflammatory cytokines TNF-alpha and IL-1beta; and up-regulated the expression of anti-inflammatory cytokines IL-10 and TGF-beta1 in the ischemic brain </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, activation of NF-kappaBeta was inhibited by LXA(4) ME treatment </plain></SENT>
<SENT sid="7" pm="."><plain>These results demonstrate that treatment of LXA(4) ME affords strong neuroprotective effect against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> reperfusion injury, and that these effects might be associated with its anti-inflammatory property </plain></SENT>
</text></document>